Direct antimicrobial susceptibility testing method for analysis of sputum collected from patients with cystic fibrosis Mohamed Zebouh, Caroline Thomas,

Slides:

Advertisements

Similar presentations

Prevalence and antimicrobial susceptibility of microorganisms isolated from sputa of patients with cystic fibrosis Giuseppe Valenza, Dennis Tappe, Doris.

Advertisements

ARFI and transient elastography for characterization of cystic fibrosis related liver disease: First longitudinal follow-up data in adult patients Thomas.

Cheryl Cameron, Mark W. Lodes, William M. Gershan

Development of resistance in Pseudomonas aeruginosa obtained from patients with cystic fibrosis at different times F.B. Spencker, L. Staber, T. Lietz,

Rapid emergence of a ceftazidime-resistant Burkholderia multivorans strain in a Cystic Fibrosis patient Joshua R. Stokell, Raad Z. Gharaibeh, Todd R.

Treatment compliance in children and adults with Cystic Fibrosis

P. Whitaker, N. Shaw, J. Gooi, C. Etherington, S. Conway, D. Peckham

R. Roberts, L. Speight, J. Lee, L. George, R. I. Ketchell, D. Lau, J

Abaigeal D. Jackson, Christopher H. Goss Journal of Cystic Fibrosis

ARFI and transient elastography for characterization of cystic fibrosis related liver disease: First longitudinal follow-up data in adult patients Thomas.

Avani C. Modi, Crystal S. Lim, Nami Yu, David Geller, Mary H

Megan R. Nelson, Craig R. Adamski, Audrey Tluczek

Amoxicillin–clavulanic acid resistance in fecal Enterobacteriaceae from patients with cystic fibrosis and healthy siblings Gwen Duytschaever, Geert Huys,

Urinary incontinence in 9��16��year olds with cystic fibrosis compared to other respiratory conditions and a normal group W.J. Browne, C.J. Wood, M.

Measures of body habitus are associated with lung function in adults with cystic fibrosis: A population-based study Doug L. Forrester, Alan J. Knox,

Microbiological yield from induced sputum compared to oropharyngeal swab in young children with cystic fibrosis Marco Zampoli, Komala Pillay, Henri Carrara,

Cirrhosis and other liver disease in cystic fibrosis

John Widger, Sarath Ranganathan, Philip J. Robinson

Controlled clinical trials in cystic fibrosis — are we doing better?

Long-term azitromycin treatment of cystic fibrosis patients with chronic Pseudomonas aeruginosa infection; an observational cohort study Christine Rønne.

Anju Anand, Elizabeth Tullis, Anne Stephenson, Preyanka Abhyankar

D. Stevens, P.J. Oades, N. Armstrong, C.A. Williams

Claire J. Tipping, Rebecca L. Scholes, Narelle S. Cox

Cystic fibrosis mortality trend in Italy from 1970 to 2011

Influence of digital clubbing on oxygen saturation measurements by pulse-oximetry in cystic fibrosis patients Filip Van Ginderdeuren, Karlien Van Cauwelaert,

Gerd Döring, Patrick Flume, Harry Heijerman, J. Stuart Elborn

Vitamin A and lung function in CF

Amyloidosis in cystic fibrosis: A case series

A.H. Gifford Journal of Cystic Fibrosis

Effectiveness of inhaled tobramycin in eradicating Pseudomonas aeruginosa in children with cystic fibrosis Sanja Stanojevic, Valerie Waters, Joseph L.

Cystic fibrosis related diabetes in an extremely young patient

Inhalation solutions — Which ones may be mixed

Antonia V. Bennett, Donald L. Patrick, James F. Lymp, Todd C

Characterisation of mutations and genotype–phenotype correlation in cystic fibrosis: Experience from India Shivaram S. Shastri, Madhulika Kabra, Sushil.

Sophia L. Markantonis, Anna Katelari, Eleni Pappa, Stavros Doudounakis

E. Tschiedel, H. Grasemann, F. Ratjen Journal of Cystic Fibrosis

Direct comparison of in vitro susceptibility of wildtype clinical Pseudomonas aeruginosa isolated from adult patients with cystic fibrosis (CF) to TOBI®

Colon Cancer in Cystic Fibrosis patients: Is this a growing problem?

Early treatment with inhaled antibiotics postpones next occurrence of Achromobacter in cystic fibrosis M. Wang, W. Ridderberg, C.R. Hansen, N. Høiby,

Felix Ratjen, Florian Brockhaus, Gerhild Angyalosi

Prevalence and risk factors for recovery of filamentous fungi in individuals with cystic fibrosis Christopher R. Sudfeld, Elliott C. Dasenbrook, William.

Stenotrophomonas maltophilia in cystic fibrosis: Improved detection by the use of selective agar and evaluation of antimicrobial resistance P. Goncalves-Vidigal,

Nasal polyposis in lung transplant recipients with cystic fibrosis

Pharmacokinetics and sputum penetration of azithromycin during once weekly dosing in cystic fibrosis patients E.B. Wilms, D.J. Touw, H.G.M. Heijerman

Novel concepts in evaluating antimicrobial therapy for bacterial lung infections in patients with cystic fibrosis Geraint B. Rogers, Lucas R. Hoffman,

Antimicrobial activity of fosfomycin and tobramycin in combination against cystic fibrosis pathogens under aerobic and anaerobic conditions Gerard McCaughey,

Nutritional decline in cystic fibrosis related diabetes: The effect of intensive nutritional intervention H. White, K. Pollard, C. Etherington, I. Clifton,

Trends in pathogens colonising the respiratory tract of adult patients with cystic fibrosis, 1985–2005 F.A. Millar, N.J. Simmonds, M.E. Hodson Journal.

Successful treatment of cepacia syndrome with a combination of intravenous cyclosporin, antibiotics and oral corticosteroids Francis J. Gilchrist, A.

H. White, A.M. Morton, S.P. Conway, D.G. Peckham

J.E. Spahr, R.B. Love, M. Francois, K. Radford, K.C. Meyer

Prevalence and antimicrobial susceptibility of microorganisms isolated from sputa of patients with cystic fibrosis Giuseppe Valenza, Dennis Tappe, Doris.

Daniel J. Smith, Gregory J. Anderson, Scott C. Bell, David W. Reid

Antibiograms of resistant Gram-negative bacteria from Scottish CF patients F.M. MacKenzie, S.V. Smith, K.E. Milne, K. Griffiths, J. Legge, I.M. Gould

D.F. Waterhouse, A.M. McLaughlin, C.G. Gallagher

CFTR modulators and pregnancy: Our work has only just begun

‘Peeling paint’ dermatitis as a presenting sign of cystic fibrosis

L. Nshimyumukiza, A. Bois, P. Daigneault, L. Lands, A. -M. Laberge, D

Beta-lactam allergy in adults with cystic fibrosis

Cheryl Cameron, Mark W. Lodes, William M. Gershan

Lutz Goldbeck, Sven Zerrer, Tim G. Schmitz Journal of Cystic Fibrosis

Khin M. Gyi, Margaret E. Hodson, Magdi Y. Yacoub

David Adeboyeku, Sandra Scott, Margaret E. Hodson

Aztreonam for inhalation solution (AZLI) in patients with cystic fibrosis, mild lung impairment, and P. aeruginosa C.E. Wainwright, A.L. Quittner, D.E.

Elisabeth P. Dellon, Margaret W. Leigh, James R. Yankaskas, Terry L

Safety, efficacy and convenience of tobramycin inhalation powder in cystic fibrosis patients: The EAGER trial Michael W. Konstan, Patrick A. Flume, Matthias.

Improved early diagnosis of Pseudomonas aeruginosa by real-time PCR to prevent chronic colonisation in a paediatric cystic fibrosis population Elaine.

Population pharmacokinetics of tobramycin administered thrice daily and once daily in children and adults with cystic fibrosis D.J. Touw, A.J. Knox,

R. D. Gray, M. Imrie, A. C. Boyd, D. Porteous, J. A. Innes, A. P

Early aggressive eradication therapy for intermittent Pseudomonas aeruginosa airway colonization in cystic fibrosis patients: 15 years experience C.R.

Presentation transcript:

Direct antimicrobial susceptibility testing method for analysis of sputum collected from patients with cystic fibrosis Mohamed Zebouh, Caroline Thomas, Patrick Honderlick, Ludovic Lemee, Christine Segonds, Frédéric Wallet, Marie-Odile Husson Journal of Cystic Fibrosis Volume 7, Issue 3, Pages 238-243 (May 2008) DOI: 10.1016/j.jcf.2007.10.002 Copyright © 2007 European Cystic Fibrosis Society Terms and Conditions

Fig. 1 Cumulative percentage of global MICs (mg/mL) of ticarcillin, ceftazidime, imipenem, aztreonam, tobramycin and ciprofloxacin inhibiting all Gram-negative bacteria. Journal of Cystic Fibrosis 2008 7, 238-243DOI: (10.1016/j.jcf.2007.10.002) Copyright © 2007 European Cystic Fibrosis Society Terms and Conditions

Fig. 2 Cumulative percentage of global MICs (mg/mL) of ticarcillin, ceftazidime, imipenem, aztreonam, tobramycin and ciprofloxacin inhibiting all Gram-negative bacteria. Journal of Cystic Fibrosis 2008 7, 238-243DOI: (10.1016/j.jcf.2007.10.002) Copyright © 2007 European Cystic Fibrosis Society Terms and Conditions